^
+ Follow DR. HAL BARRON Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1243290
                    [Title] => New drug helps people with advanced HER2-positive breast cancer live longer
                    [Summary] => 

Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.
 

[DatePublished] => 2013-10-10 00:00:00 [ColumnID] => 0 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 731565 [Title] => Treatment for advanced ovarian cancer receives positive opinion [Summary] =>

BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.

[DatePublished] => 2011-09-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 703067 [Title] => Roche's drug receives broader EU label for women with metastatic breast cancer [Summary] =>

BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.

[DatePublished] => 2011-07-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 696213 [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer [Summary] =>

Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

[DatePublished] => 2011-06-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [4] => Array ( [ArticleID] => 691717 [Title] => Roche announces new study data on rheumatoid arthritis treatment [Summary] =>

Roche recently announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress.

[DatePublished] => 2011-06-02 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [5] => Array ( [ArticleID] => 689458 [Title] => Roche bares study results on lung cancer medicine [Summary] =>

Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC).

[DatePublished] => 2011-05-26 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [6] => Array ( [ArticleID] => 682217 [Title] => Roche drug for treating systemic juvenile idiopathic arthritis gets US FDA approval [Summary] =>

The United States Food and Drug Administration (FDA) has approved Roche’s drug tocilizumab for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two and older.

[DatePublished] => 2011-05-05 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [7] => Array ( [ArticleID] => 678152 [Title] => Roche bares positive results of breast cancer drug [Summary] =>

BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.

[DatePublished] => 2011-04-21 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [8] => Array ( [ArticleID] => 671055 [Title] => Roche announces positive results for severe skin cancer medicine [Summary] =>

BASEL, Switzerland — Roche announced this week that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib, showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.

[DatePublished] => 2011-03-31 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [9] => Array ( [ArticleID] => 657719 [Title] => Treatment helps women with ovarian cancer live significantly longer [Summary] =>

Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

[DatePublished] => 2011-02-17 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
DR. HAL BARRON
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1243290
                    [Title] => New drug helps people with advanced HER2-positive breast cancer live longer
                    [Summary] => 

Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.
 

[DatePublished] => 2013-10-10 00:00:00 [ColumnID] => 0 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 731565 [Title] => Treatment for advanced ovarian cancer receives positive opinion [Summary] =>

BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.

[DatePublished] => 2011-09-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 703067 [Title] => Roche's drug receives broader EU label for women with metastatic breast cancer [Summary] =>

BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.

[DatePublished] => 2011-07-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 696213 [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer [Summary] =>

Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

[DatePublished] => 2011-06-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [4] => Array ( [ArticleID] => 691717 [Title] => Roche announces new study data on rheumatoid arthritis treatment [Summary] =>

Roche recently announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress.

[DatePublished] => 2011-06-02 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [5] => Array ( [ArticleID] => 689458 [Title] => Roche bares study results on lung cancer medicine [Summary] =>

Roche announced this week the final results from a randomized, multi-center, double-blind Phase II study with its investigational personalized medicine, MetMAb, in people with previously treated advanced non-small cell lung cancer (NSCLC).

[DatePublished] => 2011-05-26 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [6] => Array ( [ArticleID] => 682217 [Title] => Roche drug for treating systemic juvenile idiopathic arthritis gets US FDA approval [Summary] =>

The United States Food and Drug Administration (FDA) has approved Roche’s drug tocilizumab for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two and older.

[DatePublished] => 2011-05-05 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [7] => Array ( [ArticleID] => 678152 [Title] => Roche bares positive results of breast cancer drug [Summary] =>

BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.

[DatePublished] => 2011-04-21 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [8] => Array ( [ArticleID] => 671055 [Title] => Roche announces positive results for severe skin cancer medicine [Summary] =>

BASEL, Switzerland — Roche announced this week that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib, showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.

[DatePublished] => 2011-03-31 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [9] => Array ( [ArticleID] => 657719 [Title] => Treatment helps women with ovarian cancer live significantly longer [Summary] =>

Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

[DatePublished] => 2011-02-17 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with